



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH



Innovation Task Force

ITFsecretariat@ema.europa.eu



Innovation Task Force (ITF)

The European Medicines Agency's multidisciplinary forum for dialogue with stakeholders:

- An entry point to the Agency's services for promoting innovation in medicine, technologies and methods.
- Easy to approach and free of charge.
- Contributes to preparing for regulatory processes.
- Platform for exchange of information between innovators and regulators, for the benefit of public health.

The Innovation Task Force (ITF) is a multidisciplinary group that includes scientific, regulatory and legal competences. It was set up to ensure coordination across the European Medicines Agency and to provide a forum for early dialogue with applicants.

Objectives of the ITF

- Establish a platform for early dialogue with applicants, to identify scientific, legal and regulatory issues relating to emerging therapies and technologies.
- Provide regulatory advice on the eligibility of medicines for Agency procedures.
- Increase awareness and learning in emerging therapies and technologies at the Agency.
- Identify the need for specialised expertise at an early stage.
- Address the impact of emerging therapies and technologies on current scientific, legal and regulatory requirements with the Agency's committees and their working parties.

For ITF assistance, send your enquiry to:

ITFsecretariat@ema.europa.eu



ITF briefing meetings and networking

Briefing meetings

- Informal meetings to discuss scientific, technical and regulatory issues for innovative drug development.
- To give orientation during early drug development and prepare for Agency procedures.
- The scientific discussions are led by experts from the Agency's network, working parties and committees.
- The meetings are free of charge and last approximately 1.5 hours.

Eligibility for the Agency's scientific services

- For combined and borderline medicines (e.g. devices, food, cosmetics).
- To prepare, complement and reinforce existing formal procedures (e.g. CHMP scientific advice, ATMP classification and certification, and designation of orphan medicines).

European ITF network

- Aims to facilitate the creation of innovative methods and technologies in academic environments, and translation of basic research into the medicine-development process.
- A network of regulators focusing on innovation (innovation centres or innovation-technology fora).
- Supports the exchange of information and facilitates knowledge transfer, for the benefit of public health.

Areas of interest (science, medicines, health)

- Pharmacogenomics/epigenetics.
- Gene, cell and tissue-engineered products.
- Nanomedicines.
- New non-clinical methods and models.
- Biomarker and methodology development.
- Novel manufacturing/delivery methods.
- Novel statistical approaches (e.g. modelling and simulation).
- Novel clinical-trial methodology (e.g. adaptive designs).
- Synthetic biology.





EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Further information

European Medicines Agency

ITF Secretariat

7 Westferry Circus

Canary Wharf

London E14 4HB

United Kingdom

Telephone +44 (0)20 7523 7614

Facsimile +44 (0)20 7523 7040

E-mail ITFsecretariat@ema.europa.eu

Website www.ema.europa.eu